

ASSOCIATION OF COMMUNITY CANCER CENTERS OVERVIEW OF EARLY STAGE NON-SMALL CELL LUNG CANCER SURVEY RESULTS

ACCC conducted a survey of multidisciplinary providers across the United States to assess current diagnostic, staging, and treatment practices for individuals with Stage IB-IIIA non-small cell lung cancer (NSCLC). The survey received 124 responses from multidisciplinary cancer care team members practicing in 33 states. Annual lung cancer case volumes per stage (IB, IIA/ IIB, IIIA) ranged from less than 5 to more than 50.

RESPONDENT SPECIALTIES




PRACTICE LOCATIONS





TUMOR BOARDS


Multidisciplinary tumor boards were a common practice at the sites surveyed. The frequency of tumor board meetings ranged from weekly (57%) or biweekly (22%) to monthly (11%).



Less than 5 percent of respondents do not regularly meet for tumor boards or are unsure of frequency.



FREQUENTLY ORDERED TESTS



Most programs (66%) report having a standard biomarker testing protocol (21% do not and 12% were unsure).

Tissue-based biomarker testing is typically ordered by:

- Medical oncologists (46%)
- Surgeons (18%)
- Pathologists (17%)
- Pulmonologists (10%)
- Advanced Practice Providers (6%)


The most common reasons cited for not ordering biomarker testing on eligible early-stage patients with NSCLC include:

- Insurance ineligibility (25%)
- Patient refusal (13%)
- Physician believes the test is not needed (15%)
- Physician forgets to order the test (13%)



LIQUID BIOPSY

For patients with resected NSCLC, respondents report that liquid biopsy is ordered:



Liquid biopsies for resected NSCLC are typically ordered by medical oncologists (60%).



ADJUVANT TREATMENT

When a driver mutation is identified, 40% of respondents report that adjuvant targeted therapy is initiated in <50% of patients at their institution. Adjuvant treatment decisions for individuals with resected NSCLC are most often made by:







8% Surgeon

Most respondents (83%) agree that their cancer practice has the staff and resources to adequately navigate patients with early-stage NSCLC on available services and treatment options. However, only 45% report that their site assigns a nurse navigator to the majority of patients with early-stage NSCLC.



BARRIERS TO OPTIMAL CARE

Overall, respondents report the biggest barriers to providing optimal care for early-stage lung cancer at their institutions were:

- Scheduling difficulties for diagnostic procedures and/or surgery (23%)
- Patient refusal of treatment (19%)
- Breakdown in communication between patients and cancer care team members (17%)
- Inadequate staffing resources (15%)
- Limited access to certain subspecialties (14%)
- Breakdown in communication within the cancer care team (8%)

A publication from the ACCC education program, Changing Care Patterns for Patients with Early-Stage Non-Small Cell Lung Cancer (NSCLC). Learn more at accc-cancer.org/early-NSCLC.

The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. For more information, visit accc-cancer.org.

© 2023. Association of Community Cancer Centers. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without written permission.

This project is supported by:





accc-cancer.org/early-NSCLC